Silva, Glenda Nicioli da; Filoni, Leandro Toshio; Salvadori, M. C. 
; Salvadori, Daisy Maria Fávero
Source: Pathology and Oncology Research. Unidade: IF
Subjects: BIOFÍSICA, BIOLOGIA MOLECULAR, MICROSCOPIA ELETRÔNICA, ONCOLOGIA, QUIMIOTERAPIA, EXPRESSÃO GÊNICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SILVA, Glenda Nicioli da et al. Gemcitabine/Cisplatin Treatment Induces Concomitant SERTAD1, CDKN2B and GADD45A Modulation and Cellular Changes in Bladder Cancer Cells Regardless of the Site of TP53 Mutation. Pathology and Oncology Research, v. 24, n. 2, p. 407-417, 2018Tradução . . Disponível em: https://doi.org/10.1007/s12253-017-0255-x. Acesso em: 18 nov. 2024.APA
Silva, G. N. da, Filoni, L. T., Salvadori, M. C., & Salvadori, D. M. F. (2018). Gemcitabine/Cisplatin Treatment Induces Concomitant SERTAD1, CDKN2B and GADD45A Modulation and Cellular Changes in Bladder Cancer Cells Regardless of the Site of TP53 Mutation. Pathology and Oncology Research, 24( 2), 407-417. doi:10.1007/s12253-017-0255-xNLM
Silva GN da, Filoni LT, Salvadori MC, Salvadori DMF. Gemcitabine/Cisplatin Treatment Induces Concomitant SERTAD1, CDKN2B and GADD45A Modulation and Cellular Changes in Bladder Cancer Cells Regardless of the Site of TP53 Mutation [Internet]. Pathology and Oncology Research. 2018 ; 24( 2): 407-417.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1007/s12253-017-0255-xVancouver
Silva GN da, Filoni LT, Salvadori MC, Salvadori DMF. Gemcitabine/Cisplatin Treatment Induces Concomitant SERTAD1, CDKN2B and GADD45A Modulation and Cellular Changes in Bladder Cancer Cells Regardless of the Site of TP53 Mutation [Internet]. Pathology and Oncology Research. 2018 ; 24( 2): 407-417.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1007/s12253-017-0255-x
